FATE THERAPEUTICS INC 8-K

What Happened

• On May 13, 2026, Fate Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026 via a press release. The press release was furnished as Exhibit 99.1 to a Form 8‑K reporting results of operations and financial condition (Item 2.02). The filing was signed by President and CEO Bahram Valamehr, Ph.D., MBA.

Key Details

• Filing date: May 13, 2026 (Form 8‑K).
• Reporting period: Quarter ended March 31, 2026.
• Exhibit included: 99.1 — press release; 104 — cover page interactive XBRL data.
• Item reported: 2.02 (Results of Operations and Financial Condition).

Why It Matters

• This is a routine SEC disclosure that notifies investors the company has released its quarterly earnings/financial results. The Form 8‑K itself references the press release but does not include detailed financial line items in the filing text; investors should read Exhibit 99.1 (the press release) and the company’s upcoming quarterly report (10‑Q) for complete revenue, earnings, cash position and guidance details.
• For retail investors: review the attached press release and any related investor presentation or earnings call to see how the quarter’s revenue, expenses, and clinical or pipeline updates may affect the stock. This 8‑K confirms timely public reporting of Fate’s quarterly results.